| Miao Zhang,Jianing qiu,Shuxian Qu,Yaling Han,Zhaozhe Liu,xiaodong xie. The clinical observation of neoadjuvant chemotherapy in locally advanced breast cancer with DX regimen. Oncol Transl Med, 2014, 13: 515-517. |
| 多西他赛联合卡培他滨新辅助化疗方案治疗局部晚期乳腺癌的临床观察 |
| The clinical observation of neoadjuvant chemotherapy in locally advanced breast cancer with DX regimen |
| Received:September 19, 2014 Revised:November 03, 2014 |
| DOI：10.1007/s10330-314-0006-8 |
| 中文关键词: 乳腺癌 新辅助化疗 多西他赛 卡培他滨 |
| 英文关键词: breast cancer; neoadjuvant chemotherapy; docetaxel; capecitabine |
| 基金项目:1. 国家十二五重大新药创制平台子课题（2012ZX09303016-002） 2. 2012年辽宁省科技攻关计划课题（2012225019） |
| Author Name | Affiliation | Department | | Miao Zhang | Graduate School, Dalian Medical University, Dalian 116044, China | Graduate School, Dalian Medical University, Dalian 116044, China | | Jianing qiu | Graduate School, Dalian Medical University, Dalian 116044, China | Graduate School, Dalian Medical University, Dalian 116044, China | | Shuxian Qu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | | | Yaling Han | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | | | Zhaozhe Liu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | | | xiaodong xie* | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China |
|
| Hits: 10291 |
| Download times: 11828 |
| 中文摘要: |
| 摘要：目的：探讨局部晚期乳腺癌应用DX(多西他赛联合卡培他滨)方案行新辅助化疗的近期临床疗效及不良反应。方法：对应用DX方案新辅助化疗4周期的局部晚期乳腺癌患者72例进行回顾性分析，具体方案：多西他赛75mg／m2，第1天静滴；卡培他滨2000 mg／m2 ，2次口服，第1～14天，21天为1周期。结果：72例患者均可评价疾病疗效，总有效率(RR)为80.5％（58/72），其中获得病理完全缓解(pCR)为7(9.7％)例，临床完全缓解（cCR）15（20.8% ）例，临床部分缓解（PR）43（59.7%）例，疾病稳定（SD）8（11.1%）例，疾病进展（PD）6（8.3%）例。不良反应主要表现为消化道反应及骨髓抑制，多为Ⅰ级或Ⅱ级，Ⅲ/Ⅳ级不良反应主要表现为6例手足综合征（15.2%）及7例粒细胞减少（20.6%）。结论： DX方案是局部晚期乳腺癌新辅助化疗的有效方案且耐受性良好。 |
| 英文摘要: |
| Objective: The recent clinical curative effect and adverse events of docetaxel and capecitabine (DX) of neoadjuvant chemotherapy in patients with locally advanced breast cancer was discussed. Methods: The data of 72 cases of neoadjuvant chemotherapy (DX) in locally advanced breast cancer after 4 cycles were retrospectively analyzed. Docetaxel 75 mg/m2 by infusion 1 h on d1, capecitabine 2000 mg/m2 by oral for twice daily on d1–14, 21 days was a cycle. Results: All 72 patients were assessed for efficacy and adverse events. The total effective rate was 80.5% (58/72), including pathological complete response (pCR) was 7 (9.7%), clinical complete remission (cCR) was 15(20.8%), clinical partial response (PR) was 43 (59.7%), stable disease (SD) was 8 (11.1%) and progressive disease (PD) was 6 (8.3%). The main adverse events were gastrointestinal reactions and bone marrow suppression. The 3 to 4 degrees of adverse reactions including granulocytopenia in 7 patients (20.6%), hand-foot syndrome in 6 patients (15.2%). Conclusion: The DX regimen provide a favorable efficacy and safety profile in patients with locally advanced breast cancer for neoadjuvant chemotherapy. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|